

Mayo Clinic Updates in CAR-T Cell Therapy 2021 – LIVESTREAM

August 26 – 27, 2021
Central Time Zone

Thursday, August 26, 2021

General Session

9:50am	Opening Remarks / Welcome <i>Saad J. Kenderian, M.B., Ch.B. and Yi Lin, M.D., Ph.D.</i>
10:00am	B-Cell Acute Lymphoblastic Leukemia: CD19 Targeting – Current status and limitations and Beyond CD19 – Future Directions <i>Nirali N. Shah, M.D., M.H.Sc., NIH</i> <i>Haneen Shalabi, D.O., NIH</i>
10:45 am	Non-Hodgkin's Lymphoma <i>Tanya Siddiqi, M.D., City of Hope (Clinical Trials/Research)</i> <i>Sattva S. Neelapu, M.D., MD Anderson Cancer Center (Real World Practice)</i>
11:30am	Multiple Myeloma <i>Nina Shah, M.D., University of California San Francisco</i>
12:00pm	Break
12:30pm	Toxicity – CRS/ICANS <i>Jae Park, M.D., Memorial Sloan Kettering Cancer Center</i>
1:00pm	TBD <i>Keynote speaker: Carl H. June, M.D., U Penn</i>
1:45pm	Challenges of CAR-T and COVID-19 <i>Hemant S. Murthy, M.D.</i>
2:15pm	Wrap-Up/Closing Remarks – reminders about the next day's session
2:30pm	<i>Adjourn</i>

Friday, August 27, 2021

Concurrent Sessions

#1 – Clinical Research

9:50am	Day 2 Opening Remarks / Welcome <i>Saad J. Kenderian, M.B., Ch.B. and Yi Lin, M.D., Ph.D.</i>
10:00am	T-cell Lymphoma: CD5, CD7 <i>LaQuisa Hill, MD, M.D., Baylor College of Medicine</i>
10:30am	CD30 CART <i>Barbara Savoldo, M.D., Ph.D., UNC School of Medicine</i>
11:00am	GBM CART <i>Christine Brown, Ph.D., City of Hope</i>
11:30am	Other CART Innovations <i>Hong Qin, M.D., Ph.D.</i>
12:00pm	Break
12:30pm	iPSC and other Off-the-Shelf IEC Platforms <i>Januario E. Castro, M.D., Mayo Clinic Arizona</i>
1:00pm	CAR-NK <i>May Daher</i>
1:30pm	UCART <i>Reuben Benjamin, UCL</i>

2:00 pm	Break (as we transition to general session)
#2 – Immune Effector Cell Program Administration – Group Discussions	
9:50am	Day 2 Opening Remarks / Welcome <i>Eapen K. Jacob, M.D. and Matthew A. Hathcock</i>
10:00am	CIBMTR and Regulatory Reporting <i>Matthew A. Hathcock</i>
10:30am	FACT IEC Program New Standards and Virtual Inspections <i>Eapen K. Jacob, M.D.</i>
11:00am	Working with a Commercial Manufacturer <i>Michael C. Deeds and Alexis A. Jackson, M.S.</i>
11:30am	Industry Manufacturer and FDA Approved Therapies <i>Gina M. Lange, R.N.</i>
12:00pm	Break
12:30pm	Logistics of Clinical Trials <i>Jared L. Bruggeman, CCRP</i>
1:15pm	Coordinating Institutional Resources for Commercial and In-house Manufactured Products <i>Hollie L. Benson and Michael P. Gustafson, Ph.D.</i>
2:00pm	Break (as we transition to general session)
#3 – Immune Effector Cell Program Provider Team – Group Discussions	
9:50am	Day 2 Opening Remarks / Welcome <i>Urshila Durani, M.D., M.P.H. and Megan T. Spychalla, P.A.-C.</i>
10:00am	Case Studies: <i>Allison (Alli) L. McClanahan, APRN, C.N.P.</i>
10:45am	Outpatient Practice <i>Megan T. Spychalla, P.A.-C.</i>
11:15am	Supportive Management <i>Adrienne N. Nedved, Pharm.D., R.Ph. or Jason N. Barreto, Pharm.D.</i>
11:45am	Complications <i>Adrienne N. Nedved, Pharm.D., R.Ph. or Jason N. Barreto, Pharm.D.</i>
12:15pm	Break
12:45pm	Long-term Follow Up <i>Urshila Durani, M.D., M.P.H.</i>
1:15pm	Grant and Supportive Resources <i>Emily R. Blackmer, M.S.W.</i>
2:00pm	Break (transition to general session)
2:15pm	Breakout Session Recap (15 min. each, we can make is 20 if needed) <ul style="list-style-type: none"> • #1 – MD, Ph. D, Research Focused • #2 – Immune Effector Cell Program Administration • #3 – Immune Effector Cell Program Provider Team
3:00pm	Course Wrap-Up
3:15pm	Adjourn



Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 8.0 knowledge-based contact hours. Participants should only claim credit commensurate with the extent of their participation in the activity.

Universal Activity Number (UAN): JA0000238-0000-21-090-L01-P